You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 17, 2025

CLINICAL TRIALS PROFILE FOR CARBAMAZEPINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for CARBAMAZEPINE

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00000191 ↗ Carbamazepine Treatment for Cocaine Dependence - 5 Completed National Institute on Drug Abuse (NIDA) Phase 2 1991-01-01 The purpose of this study is to assess carbamazepine as a pharmacotherapy for cocaine dependence.
NCT00000191 ↗ Carbamazepine Treatment for Cocaine Dependence - 5 Completed University of Pennsylvania Phase 2 1991-01-01 The purpose of this study is to assess carbamazepine as a pharmacotherapy for cocaine dependence.
NCT00000217 ↗ Pharmacotherapy and Intensive Treatment of Drug Abuse - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 1990-09-01 The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.
NCT00000217 ↗ Pharmacotherapy and Intensive Treatment of Drug Abuse - 1 Completed US Department of Veterans Affairs Phase 2 1990-09-01 The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.
NCT00000217 ↗ Pharmacotherapy and Intensive Treatment of Drug Abuse - 1 Completed VA Office of Research and Development Phase 2 1990-09-01 The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.
NCT00000217 ↗ Pharmacotherapy and Intensive Treatment of Drug Abuse - 1 Completed University of Kansas Phase 2 1990-09-01 The purpose of this study is to evaluate desipramine and carbamazepine in reducing cocaine craving; increase outpatient treatment capacity and evaluate their incidence of psychiatric disorders.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 6 of 6 entries

Clinical Trial Conditions for CARBAMAZEPINE

Condition Name

3517128005101520253035EpilepsyBipolar DisorderHealthySeizures[disabled in preview]
Condition Name for CARBAMAZEPINE
Intervention Trials
Epilepsy 35
Bipolar Disorder 17
Healthy 12
Seizures 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

49221716005101520253035404550EpilepsyBipolar DisorderSeizuresDisease[disabled in preview]
Condition MeSH for CARBAMAZEPINE
Intervention Trials
Epilepsy 49
Bipolar Disorder 22
Seizures 17
Disease 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CARBAMAZEPINE

Trials by Country

+
Trials by Country for CARBAMAZEPINE
Location Trials
United States 168
Italy 24
Germany 21
Australia 16
United Kingdom 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for CARBAMAZEPINE
Location Trials
Maryland 14
New York 12
Kansas 10
North Carolina 10
Texas 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CARBAMAZEPINE

Clinical Trial Phase

34.5%20.5%41.5%0010203040506070Phase 4Phase 3Phase 2/Phase 3[disabled in preview]
Clinical Trial Phase for CARBAMAZEPINE
Clinical Trial Phase Trials
Phase 4 59
Phase 3 35
Phase 2/Phase 3 6
[disabled in preview] 71
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

65.4%10.1%9.5%15.1%0102030405060708090100110120CompletedRecruitingUnknown status[disabled in preview]
Clinical Trial Status for CARBAMAZEPINE
Clinical Trial Phase Trials
Completed 117
Recruiting 18
Unknown status 17
[disabled in preview] 27
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CARBAMAZEPINE

Sponsor Name

trials024681012141618Johnson & Johnson Pharmaceutical Research & Development, L.L.C.UCB PharmaGlaxoSmithKline[disabled in preview]
Sponsor Name for CARBAMAZEPINE
Sponsor Trials
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 10
UCB Pharma 7
GlaxoSmithKline 7
[disabled in preview] 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

55.3%33.6%6.6%0020406080100120140160180OtherIndustryNIH[disabled in preview]
Sponsor Type for CARBAMAZEPINE
Sponsor Trials
Other 176
Industry 107
NIH 21
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Carbamazepine: Clinical Trials, Market Analysis, and Projections

Introduction to Carbamazepine

Carbamazepine is a medication widely used in the treatment of epilepsy, manic episodes of bipolar disorder, and trigeminal neuralgia. Its versatility and efficacy have made it a staple in the pharmaceutical industry. Here, we will delve into the current clinical trials, market analysis, and future projections for carbamazepine.

Clinical Trials Involving Carbamazepine

Pharmacokinetics and Drug Interactions

Several clinical trials are ongoing to understand the pharmacokinetics of carbamazepine and its interactions with other drugs. For instance, a Phase I study by AstraZeneca (Study identifier: D8532C00006) investigates the effect of carbamazepine on the pharmacokinetics of camizestrant (AZD9833) and midazolam. This study involves healthy postmenopausal female participants and assesses the impact of carbamazepine, a CYP3A4/5 inducer, on camizestrant exposure[1].

Another study (Study identifier: D7960C00011) by AstraZeneca examines the pharmacokinetics of AZD0780 when administered alone and in combination with carbamazepine and itraconazole. This open-label, fixed sequence study in healthy participants aims to understand the drug interactions and their effects on pharmacokinetics[4].

Importance of These Trials

These trials are crucial for understanding how carbamazepine interacts with other medications, which is vital for ensuring patient safety and optimizing treatment regimens. By determining the pharmacokinetic profiles, healthcare providers can better manage potential drug interactions and side effects.

Market Analysis of Carbamazepine

Current Market Size and Growth

The global carbamazepine market has been experiencing significant growth. As of 2023, the market size was valued at $713.4 billion and is projected to reach $958.77 billion by 2030, growing at a CAGR of 3.3% during the forecast period from 2023 to 2030[3].

Market Drivers

Several factors are driving the growth of the carbamazepine market:

  • Increasing Prevalence of Epilepsy: The dynamic growth of the epilepsy market, particularly among the mid-teen age group, presents lucrative opportunities for carbamazepine. In the U.S., the use of newer therapies for epilepsy and bipolar depression has seen a significant increase[2].
  • Expanding Applications: Carbamazepine is approved for various conditions, including epilepsy, manic episodes of bipolar disorders, trigeminal neuralgia, and other neurological disorders. Its use in treating alcohol withdrawal disorders, central partial diabetes insipidus, and psychotic disorders further boosts its demand[2].
  • Controlled Release Formulations: The availability of controlled release formulations, which provide fewer side effects, has also contributed to the market growth[2].

Competitive Landscape

The carbamazepine market is highly competitive, with several key players such as Novartis, Apotex Corporation, Teva, Biomed Pharma, Nucare Pharmaceuticals, and Taro Pharmaceuticals. These companies are continuously innovating and expanding their product portfolios to maintain their market share[3].

Market Projections

Forecast Period

The global carbamazepine market is expected to continue its growth trajectory from 2025 to 2031. Market reports forecast revenue growth at the global, regional, and country levels, providing a detailed analysis of industry trends and opportunities[5].

Regional Analysis

The market is segmented geographically into North America, Europe, Asia Pacific, and the rest of the world. Each region presents unique opportunities and challenges, with varying demand driven by local healthcare needs and regulatory environments[3].

Market Trends and Opportunities

  • Increasing Demand for New Therapies: The growing need for effective treatments for epilepsy and other neurological disorders is driving innovation in the carbamazepine market. New formulations and delivery methods are being developed to improve patient outcomes[2].
  • Regulatory Approvals: Recent approvals and the potential for future approvals of new formulations and indications will continue to drive market growth[2].

Challenges and Restraints

Side Effects and Drug Interactions

Despite its efficacy, carbamazepine is associated with several side effects and drug interactions. These can include severe reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis, as well as interactions with other medications that can alter its pharmacokinetics[1][4].

Regulatory Scrutiny

The pharmaceutical industry is heavily regulated, and any changes in regulatory policies can impact the market. Strict guidelines and safety protocols must be adhered to, which can sometimes slow down the approval process for new formulations or indications[5].

Key Takeaways

  • Clinical Trials: Ongoing clinical trials are crucial for understanding the pharmacokinetics and drug interactions of carbamazepine, ensuring safer and more effective treatment regimens.
  • Market Growth: The global carbamazepine market is expected to grow significantly, driven by increasing demand for treatments of epilepsy and other neurological disorders.
  • Competitive Landscape: The market is highly competitive, with key players continuously innovating to maintain their market share.
  • Regional Variations: Market demand varies by region, influenced by local healthcare needs and regulatory environments.

FAQs

What are the primary uses of carbamazepine?

Carbamazepine is primarily used for the treatment of epilepsy, manic episodes of bipolar disorders, and trigeminal neuralgia.

What are the potential side effects of carbamazepine?

Carbamazepine can cause severe side effects such as Stevens-Johnson syndrome and toxic epidermal necrolysis, as well as less severe side effects like dizziness and nausea.

How does carbamazepine interact with other medications?

Carbamazepine is a CYP3A4/5 inducer and can interact with other medications, altering their pharmacokinetics. Clinical trials are ongoing to understand these interactions better.

What is the projected growth rate of the carbamazepine market?

The global carbamazepine market is projected to grow at a CAGR of 3.3% from 2023 to 2030.

Which companies are key players in the carbamazepine market?

Key players include Novartis, Apotex Corporation, Teva, Biomed Pharma, Nucare Pharmaceuticals, and Taro Pharmaceuticals.

Sources

  1. AstraZeneca Clinical Trials: A Study to Investigate the Pharmacokinetics of Midazolam after Repeated Oral Doses of Camizestrant.
  2. Biospace: Carbamazepine Market is expected to expand at a healthy growth rate by 2025 | TMR Research Study.
  3. Verified Market Reports: Carbamazepine Market Size, Share, Scope, Trends And Forecast.
  4. AstraZeneca Clinical Trials: A study to investigate the pharmacokinetics of AZD0780 when administered alone and in combination with itraconazole and carbamazepine.
  5. Cognitive Market Research: Carbamazepine Market Report 2024 (Global Edition).

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.